Table 1.

Summary of the efficacy responses after 12 and 24 weeks treatment

	Placebo	50mg	100mg	200mg
	(n=72)	(n=72)	(n=70)	(n=69)

12 weeks
ACR20, NRI¹, %	29	67***	66***	73**
ACR50, NRI, %	11	35**	37***	44***
ACR70, NRI, %	3	8	19**	13*
DAS28(CRP), LOCF³, mean change from BL²	−1.0	−1.8***	−2.0***	−2.3***
CDAI⁴ mean change from BL, LOCF	−12	−21***	−24***	−25***
24 weeks
ACR20, NRI, %	n/a	57	79	67
ACR50, NRI, %	n/a	33	39	45
ACR70, NRI, %	n/a	19	26	25
DAS28(CRP), LOCF, mean change from BL	n/a	−2.0	−2.6	−2.6
CDAI mean change from BL, LOCF	n/a	−22	−30	−28

*p<0.05 vs. placebo; **p<0.01 vs. placebo; ***p<0.001 vs. placebo. ACR scores based on ITT analysis. ¹Non-responder imputation. ²Baseline. ³Last observation carried forward. ⁴Clinical Disease Activity Index.